Allergy Therapeutics (LON:AGY) Reaches New 52-Week Low – Should You Sell?

Allergy Therapeutics plc (LON:AGYGet Free Report)’s share price hit a new 52-week low during trading on Thursday . The stock traded as low as GBX 5 and last traded at GBX 5.90, with a volume of 143181 shares changing hands. The stock had previously closed at GBX 5.50.

Allergy Therapeutics Price Performance

The firm’s fifty day moving average price is GBX 7.82 and its 200 day moving average price is GBX 9.82. The firm has a market capitalization of £373.62 million, a PE ratio of -6.08, a P/E/G ratio of -30.70 and a beta of 0.87. The company has a current ratio of 1.13, a quick ratio of 1.48 and a debt-to-equity ratio of 629.58.

About Allergy Therapeutics

(Get Free Report)

Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development.

See Also

Receive News & Ratings for Allergy Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergy Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.